Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viatris Focuses On Being First In Race For Eylea Biosimilar

‘We Will Be Filing Within This Year’ Indicates Viatris President Malik

Executive Summary

Viatris has reiterated the strength of its biosimilars and complex generics pipeline, highlighting opportunities including biosimilar Eylea, Botox and once-a-month Copaxone.

You may also be interested in...



Viatris Expects First Interchangeable Biosimilar Designations For Insulins In July

Amid continued debate over biosimilar interchangeability in the US, Viatris has said it expects to pick up the first such approvals later this year with the company’s insulin glargine and insulin aspart biosimilar products.

Teva Remains Neutral On Erosion Worries After Sandoz Remarks

Teva was drawn into the conversation around generic price erosion, especially in the US and Europe, after Sandoz singled out the unfavorable effect during a lackluster Q1.

Viatris Reveals Generic Rybelsus Candidate As Part Of Continued Complex Push

Recently-formed Viatris is looking to build on the success of several high-margin complex generics launches, including versions of Advair and Copaxone, by developing further candidates, including rivals to Novo Nordisk’s Rybelsus (semaglutide) and Victoza (liraglutide).

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150999

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;